アデノ随伴ウイルス
Proceedings of the National Academy of Sciences of the United States of America 82 (23): 7919–23. doi:10.1073/pnas.82.23.7919. PMC 390881. PMID 2999784. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC390881/.
↑ Cassinotti P, Weitz M, Tratschin JD (November 1988). “Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1”. Virology 167 (1): 176–84. doi:10.1016/0042-6822(88)90067-0. PMID 2847413.
1 2 Muralidhar S, Becerra SP, Rose JA (January 1, 1994). “Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity”. Journal of Virology 68 (1): 170–6.
PMC 236275. PMID 8254726. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=8254726.
↑ Trempe JP, Carter BJ (September 1, 1988). “Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein”. Journal of Virology 62 (9): 3356–63. PMC 253458. PMID 2841488. http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=2841488.
↑ Rabinowitz JE, Samulski RJ (December 2000). “Building a better vector: the manipulation of AAV virions”. Virology 278 (2): 301–8. doi:10.1006/viro.2000.0707. PMID 11118354.
↑ Girod A, Wobus CE, Zádori Z, et al. (May 1, 2002). “The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity”.
“Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B..”. J Transl Med. 12. doi:10.1186/1479-5876-12-25. PMC 3904690. PMID 24460861. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3904690/.
↑ J. of Gene Medicine, http://www.abedia.com/wiley/vectors.php
↑ Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis The New England journal of medicine, 358(21), 2240–2248. doi:10.1056/NEJMoa0802315
↑ Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., et al. (2008).
AAV6, a hybrid of AAV1 and AAV2, also shows lower immunogenicity than AAV2.
Serotypes can differ with the respect to the receptors they are bound to. For example AAV4 and AAV5 transduction can be inhibited by soluble sialic acids (of different form for each of these serotypes), and AAV5 was shown to enter cells via the platelet-derived growth factor receptor.